Patients with diabetes-related chronic kidney disease (CKD) are at high risk for a number of adverse events over a relatively short period of time. So what do we have in terms of efficacious therapies that can help make a positive impact in that regard? Here to share what we need to know about non-steroidal mineralocorticoid receptor antagonists (MRAs) for the treatment of diabetes-related CKD is Dr. Mikhail Kosiborod, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute.